Compare Archer-Daniels-Midland Co (ADM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Merck & Co., Inc. — how do they compare? Archer-Daniels-Midland Co trades at $80.56 (market cap $38.43B), while Merck & Co., Inc. trades at $134.86 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 8.5× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| ADM | MRK | |
|---|---|---|
Market Cap | $38.43B | $327.94B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $132.93 |
52-Week Low | $56.00 | $77.60 |
Enterprise Value | $46.68B | $374.70B |
Dividend Yield | 2.61% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
Merck (MRK) trades at $134.36, up 3.0% today, with a bullish technical signal and strong institutional buying. The stock exhibits robust fundamentals with 2025 revenue of $65.01B and net income of $18.25B, though a high P/E of 106.34 suggests premium valuation. Recent acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, supported by positive earnings beats in recent quarters.
Outlook remains positive with a consensus price target of $140.58, though risks include high debt levels and competitive pressures. The stock offers a steady dividend and growth potential from strategic M&A, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
